Englander Institute for Precision Medicine
Found 797 results
Author Title Type [ Year(Asc)]
Filters: Clinical-trials-corner-issue-10(1) is   [Clear All Filters]
2022
Park J, Foox J, Hether T, Danko DC, Warren S, Kim Y, Reeves J, Butler DJ, Mozsary C, Rosiene J et al..  2022.  System-wide transcriptome damage and tissue identity loss in COVID-19 patients.. Cell Rep Med. 3(2):100522.
Petroni G, Buqué A, Coussens LM, Galluzzi L.  2022.  Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment.. Nat Rev Drug Discov. 21(6):440-462.
van der Mijn JC, Chen Q, Laursen KB, Khani F, Wang X, Dorsaint P, Sboner A, Gross SS, Nanus DM, Gudas LJ.  2022.  Transcriptional and metabolic remodeling in clear cell renal cell carcinoma caused by ATF4 activation and the integrated stress response (ISR).. Mol Carcinog. 61(9):851-864.
Ciccarese C, Iacovelli R, Sternberg CN, Gillessen S, Tortora G, Fizazi K.  2022.  Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis.. Eur J Cancer. 173:276-284.
Alnajar H, Ravichandran H, Rendeiro AFigueiredo, Ohara K, Zoughbi WAl, Manohar J, Greco N, Sigouros M, Fox J, Muth E et al..  2022.  Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab.. Cold Spring Harb Mol Case Stud. 8(3)
Schad SE, Chow A, Mangarin L, Pan H, Zhang J, Ceglia N, Caushi JX, Malandro N, Zappasodi R, Gigoux M et al..  2022.  Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions.. J Exp Med. 219(6)
Yu H, Sfakianos JP, Wang L, Hu Y, Daza J, Galsky MD, Sandhu HS, Elemento O, Faltas BM, Farkas AM et al..  2022.  Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT-Stromal and Tgfβ-Dependent Mechanisms.. Mol Cancer Ther. 21(11):1729-1741.
Lord BD, Martini RN, Davis MB.  2022.  Understanding how genetic ancestry may influence cancer development.. Trends Cancer. 8(4):276-279.
Roberts LR, Rivers BM, Yates CC, Newman LA, Sarkodie BD, Davis MB, Asare-Aboagye Y, Adjei AA, Harris AE, Awuah B.  2022.  Unmet Needs in Oncology Clinical Research and Treatment in Africa: Focus on Ghana.. Oncologist. 27(9):760-767.
Kim J, Rustam S, Mosquera JMiguel, Randell SH, Shaykhiev R, Rendeiro AF, Elemento O.  2022.  Unsupervised discovery of tissue architecture in multiplexed imaging.. Nat Methods. 19(12):1653-1661.
Mordoh A, Aris M, Carri I, Bravo AInés, Podaza E, Pardo JCarlos Tri, Cueto GRubén, Barrio MMarcela, Mordoh J.  2022.  An Update of Cutaneous Melanoma Patients Treated in Adjuvancy With the Allogeneic Melanoma Vaccine VACCIMEL and Presentation of a Selected Case Report With In-Transit Metastases.. Front Immunol. 13:842555.
Batra R, Uni R, Akchurin OM, Alvarez-Mulett S, Gómez-Escobar LG, Patino E, Hoffman KL, Simmons W, Chetnik K, Buyukozkan M et al..  2022.  Urine-based multi-omic comparative analysis of COVID-19 and bacterial sepsis-induced ARDS.. medRxiv.
Malla M, Loree JM, Kasi PMurtaza, Parikh ARaj.  2022.  Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices.. J Clin Oncol. 40(24):2846-2857.
Rajappa P, Eng KW, Bareja R, Bander ED, Yuan M, Dua A, Maachani UBhanu, Snuderl M, Pan H, Zhang T et al..  2022.  Utility of multimodality molecular profiling for pediatric patients with central nervous system tumors.. Neurooncol Adv. 4(1):vdac031.
Gomari DP, Schweickart A, Cerchietti L, Paietta E, Fernandez H, Al-Amin H, Suhre K, Krumsiek J.  2022.  Variational autoencoders learn transferrable representations of metabolomics data.. Commun Biol. 5(1):645.
Brendel M, Getseva V, Assaad MAl, Sigouros M, Sigaras A, Kane T, Khosravi P, Mosquera JMiguel, Elemento O, Hajirasouliha I.  2022.  Weakly-supervised tumor purity prediction from frozen H&E stained slides.. EBioMedicine. 80:104067.
Barratt CLR, Wang C, Baldi E, Toskin I, Kiarie J, Lamb DJ.  2022.  What advances may the future bring to the diagnosis, treatment, and care of male sexual and reproductive health? Fertil Steril. 117(2):258-267.
Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M et al..  2022.  What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.. Eur Urol. 82(1):6-11.
De Giorgi U, Hussain M, Shore N, Fizazi K, Tombal B, Penson D, Saad F, Efstathiou E, Madziarska K, Steinberg J et al..  2022.  Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide? Future Oncol. 18(35):3867-3874.
Lobo J, Ohashi R, Amin MB, Berney DM, Compérat EM, Cree IA, Gill AJ, Hartmann A, Menon S, Netto GJ et al..  2022.  WHO 2022 landscape of papillary and chromophobe renal cell carcinoma.. Histopathology. 81(4):426-438.
Cyrta J, Rosiene J, Bareja R, Kudman S, Zoughbi WAl, Motanagh S, Wilkes DC, Eng K, Zhang T, Sticca E et al..  2022.  Whole-genome characterization of myoepithelial carcinomas of the soft tissue.. Cold Spring Harb Mol Case Stud. 8(7)
Santambrogio L, Franco A.  2022.  The yin/yang balance of the MHC-selfimmunopeptidome.. Front Immunol. 13:1035363.
2021
Clement CC, D'Alessandro A, Thangaswamy S, Chalmers S, Furtado R, Spada S, Mondanelli G, Ianni F, Gehrke S, Gargaro M et al..  2021.  3-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine.. Nat Commun. 12(1):4447.
Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V et al..  2021.  Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.. Lancet Oncol. 22(4):525-537.
Motzer RJ, Russo P, Haas N, Doehn C, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JLyun, Lim HYeong et al..  2021.  Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial.. Eur Urol. 79(3):334-338.